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Abstract
National Kidney Foundation CKD staging has allowed uniformity in studies on CKD. However, early diagnosis and predicting
progression to end stage renal disease are yet to be improved. Seventy six patients with different levels of CKD, including
outpatients and dialysed patients were studied for transcriptome, metabolome and proteome description. High resolution
urinary proteome analysis was blindly performed in the 53 non-anuric out of the 76 CKD patients. In addition to routine
clinical parameters, CKD273, a urinary proteomics-based classifier and its peptides were quantified. The baseline values were
analyzed with regard to the clinical parameters and the occurrence of death or renal death during follow-up (3.6 years) as
the main outcome measurements. None of the patients with CKD273,0.55 required dialysis or died while all fifteen patients
that reached an endpoint had a CKD273 score .0.55. Unsupervised clustering analysis of the CKD273 peptides separated
the patients into two main groups differing in CKD associated parameters. Among the 273 biomarkers, peptides derived
from serum proteins were relatively increased in patients with lower glomerular filtration rate, while collagen-derived
peptides were relatively decreased (p,0.05; Spearman). CKD273 was different in the groups with different renal function
(p,0.003). The CKD273 classifier separated CKD patients according to their renal function and informed on the likelihood of
experiencing adverse outcome. Recently defined in a large population, CKD273 is the first proteomic-based classifier
successfully tested for prognosis of CKD progression in an independent cohort.
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Introduction
Chronic kidney disease (CKD), by its high prevalence [1] and
major impact on national care budgets [2,3] is a concerning public
health problem. The Global Burden Disease Study report has
recently identified an increase in age standardized death rates
from CKD, confirming these concerns [4] and measures are
presently directed to early detection of CKD and prevention of its
complications in order to improve survival and quality of life [5].
Among the causes of CKD, primary glomerular diseases have
recently been overtaken by diabetes [2], which is increasingly
observed even in young populations [6] and is associated with
increased morbidity and mortality [7]. Despite different aetiolo-
gies, similar changes in renal architecture and function are
observed with CKD progression. Still, the pathophysiology of
renal disease is not completely elucidated and estimating the
likelihood of disease progression is of utmost importance, as it
influences follow-up and treatment.
In 2002, the National Kidney Foundation proposed a definition
and classification of CKD, based on renal damage markers and
serum creatinine-based estimation of glomerular filtration rate
(eGFR) [8]. This classification has allowed unifying and standard-
izing CKD, thereby enabling better assessment of the natural
history of CKD, independently of the aetiology, as well as to
evaluate the efficacy of different treatments in improving
outcomes. However, the classical renal function markers (serum
creatinine level and GFR) are recognised to be late markers of
disease, as organ damage forcedly precedes functional modifica-
tions such as filtration impairment. Single urinary markers, such as
albumin, N-acetyl-glucosaminidase [9], a1-microglobulin [10], or
neutrophil gelatinase-associated lipocalin [11] have been proposed
as earlier markers. Microalbuminuria was demonstrated to be
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linked to developing overt CKD in diabetes [12]. Albuminuria is
generally the consequence of glomerular dysfunction. Although
increased albumin excretion may in turn increase renal damage, it
is unlikely that albuminuria per se plays a significant role in the
initiation of kidney disease. The identification of molecules linked
to renal disease and likely to primarily participate in renal damage
in CKD is eagerly sought. Such factors may be of help in assessing
progression of disease, understanding pathophysiology, or, if
participating early in the disease, in informing about the likelihood
of kidney function loss [13].
Recently, significant progress has been achieved in the
proteomic analysis of multiple compounds in biological fluids
and high throughput analyses are now being applied, aiming at
screening or diagnosing disease, unraveling pathophysiology,
monitoring treatments, and establishing prognosis [14]. Proteo-
mics allowed detection of differences in the urinary proteome
between normo, micro and macroalbuminuric patients in type I
diabetes and differentiated them from other chronic renal
diseases15. Further, peptides identified in the urinary proteome
have been combined to classifying models specific for different
aetiologies of renal disease [15–19]. We have recently developed a
classifier based on 273 urinary peptides (CKD273) which reliably
allowed specific detection of CKD in a group of more than 600
patients and controls [20]. CKD273 classifier overcame the
predominant patterns related to specific diseases, and identified
CKD independently of the aetiology [20].
In the present study we investigated the classification perfor-
mance of the proteomic classifier CKD273 [20] in a blind manner
in a group of patients with different stages of CKD and assessed
the association of the CKD273 classifier with the combined
endpoint of loss of kidney function and death. The results
validated the use of CKD273 classifier in assessing CKD and
informing about outcome.
Patients and Methods
Patients
During three consecutive days, all patients eligible and
attending the outpatient clinics of the hospitals of Se`te and
Montpellier, as well as the dialysis unit in Se`te, were invited to
participate in the study. Eligible were stable patients, over 18 year-
old, not having been in hospital for over 2 months and not having
acute inflammatory diseases. A total of 76 patients were included,
of those, 53 were not anuric. Twenty seven of them were diabetics;
7 had nephroangiosclerosis, 4 interstitial nephritis, 3 chronic GN,
3 uninephrectomy, 3 autosomal dominant polycystic kidney
disease, 3 other (anticalcineurine toxicity, diuretic abuse and
sarcoidosis) and 3 unknown. For evaluation, renal function was
estimated by simplified MDRD formula [21]. Their characteristics
are given in Table 1 and the demographic, clinical and routine
chemistry data of each of the 53 patients are given in Table S1.
The study was designed and conducted fulfilling all the
requisites of the French law on the protection of individuals
collaborating in medical research and was in accordance with the
principles of the Declaration of Helsinki. Written informed
consent was obtained from all participants. The data were
handled according to the rules of the CNIL (Centre National
d’Informatique et Liberte´) warranting the respect of privacy. It was
declared to the French Ministry with the allocated reference
number DC – 2008 – 417 and was approved by the local ethics
committee, the Comite´ de Protection de Personnes (CPP) of
Montpellier.
All patients underwent clinical examination and had routine
laboratory screening including the determination of creatinine,
urea, glucose, calcium and phosphate serum levels as well as blood
cell counts, during morning. Fasting was not demanded. Fresh
urine was collected and checked for routine chemistries. Two
aliquots were frozen immediately for proteomics analyses as
described below, and stored at 280uC until analysis.
The samples were coded and shipped to the laboratory for
urinary proteomics analysis, which was performed blinded,
without any further information. The samples were unblinded
after depositing the results by the proteomics laboratory
(Mosaiques).
The patients were subsequently seen regularly in the outpatient
clinic and clinical and laboratory data recorded. Physicians were
not informed of CKD273 classifier scoring. Patient management
during the follow-up period was only based on normal practice.
When patients did not attend the clinic, data were obtained from
general practitioners. Deaths or initiation of renal replacement
therapy were assessed as a combined endpoint. After 3.6 years of
follow-up, outcome was obtained from 49 patients (4 patients were
lost-to-follow up, 7.5%). Fifteen patients reached an endpoint. Of
those, nine patients started dialysis and six patients died not being
on dialysis. Thirty-three patients did not reach an endpoint. One
patient was transplanted and was not included in the follow-up
analyses.
Methods
Sample preparation
Samples were prepared as described [20]: a 0.7 mL aliquot
stored urine was thawed and diluted with 0.7 mL 2 M urea,
10 mM NH4OH containing 0.02% SDS. Samples were filtered
using Centrisart ultracentrifugation filter devices (20 kDa cut-off;
Sartorius, Goettingen, Germany) at 3,000 g until 1.1 mL of filtrate
was obtained. Subsequently, filtrate was desalted using PD-10
column (GE Healthcare, Sweden) equilibrated in 0.01% NH4OH
Table 1. Patients’ characteristics.
N 53
M/F 33/20
D/ND 27/26
Age (years) 7061.6
Serum creatinine (mmol/L) 249623
CRP (mg/L) 4.2260.51
WCC (cell/mm3) 66986272
Hemoglobin (mg/dL) 13.160.2
Glycated Hemoglobin (%) 6.360.2
Serum proteins (g/L) 72.560.9
Serum calcium (mmol/L) 2.2860.02
Serum phosphate (mmol/L) 1.1960.03
Alkaline phosphatase (UI/L) 71.464.2
iPTH (pmol/L) 18.7563.2
Urine proteins (g/g of creatinine) 1.1860.32
eGFR (mL/min/1.73 m2)* 36.0162.98
Abbreviations: CRP (C reactive protein); WCC (white cell counts), iPTH (intact
parathyroid hormone); eGFR (estimated glomerular filtration rate).
For continuous variables, results are presented as mean 6SEM.
*6 patients were treated with haemodialysis. The eGFR and urinary
concentration of creatinine do not apply to these patients given that creatinine
levels vary following dialysis treatment.
doi:10.1371/journal.pone.0062837.t001
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in HPLC-grade water. Finally, samples were lyophilized and
stored at 4uC. Shortly before CE-MS analysis, lyophilisates were
re-suspended in HPLC-grade water to a final protein concentra-
tion of 0.8 mg/mL checked by BCA assay (Interchim, Montlucon,
France).
CE-MS analysis
Capillary electrophoresis–coupled mass spectrometry (CE-MS)
analysis was performed as described [15,22,23]. The average
recovery of sample in the preparation procedure was ,85% and
the limit of detection was ,1 fmol. Mass resolution was above
8,000 Da enabling resolution of monoisotopic mass signals for
z#6. After charge deconvolution, mass accuracy was ,25 ppm
for monoisotopic resolution and ,100 ppm for unresolved peaks
(z.6). The analytical precision of the platform was assessed
extensively [15,20].
Proteomics data processing and evaluation
Mass spectral peaks representing identical molecules at different
charge states were deconvoluted into single masses using
MosaiquesVisu software [24]. Only signals with z.1 observed in
a minimum of 3 consecutive spectra with a signal-to-noise ratio of
at least 4 were considered. Reference signals of 1770 urinary
polypeptides were used for CE-time calibration by locally
weighted regression. For normalization of analytical and urine
dilution variances, signal intensities were normalized relative to 29
‘‘housekeeping’’ peptides [25]. The obtained peak lists character-
ize each polypeptide by its molecular mass [Da], normalized CE
migration time [min] and normalized signal intensity. All detected
peptides were deposited, matched, and annotated in a Microsoft
SQL database allowing further statistical analysis. For clustering,
peptides in different samples were considered identical if mass
deviation was ,50 ppm. CE migration time was controlled to be
below 0.35 minutes after calibration.
Statistical analysis
The analyses of proteomic data were performed in a blind
manner and the results (amplitude of single peptides and scoring of
the CKD273 classifier) were stored in the central data base before
unblinding. Then the codes were opened and the data were
merged for the unblinded analysis. The scorings of the CKD273
classifier were tested by general linear model (GLM) analysis for
unbalanced data. For clustering analysis, patients were assigned to
clusters based on their respective 273 proteome pattern following
an average linkage clustering using standard Euclidean distances.
The two main clusters identified were analyzed. Cluster member-
ship was taken as a two-level class variable and parametric and
non parametric tests were applied to assess differences in clinical
variables. Analyses were performed using SAS version 9.1 (SAS
inc, North Carolina, USA). The results are given as mean6 SEM.
Results
The demographic, clinical and routine chemistry data of each of
the 53 patients are given in Table 1 and Table S1. Urine samples
collected in the outpatient clinic were blindly analyzed employing
the established CE-MS proteomics platform. The resulting data
were scored with the previously established CKD273 classifier,
which combines 273 distinct urinary proteomic biomarkers
associated with CKD into one numeric variable. Figure 1 presents
illustrative examples of urinary proteomes of two included patients
at different stages of CKD.
General linear model (GLM) analyses of the CKD273 classifier
showed a significant difference in the patients distributed
according to their eGFR into 4 different groups following the
National Kidney Foundation classification (stages I-II, III, IV and
V CKD) (F = 19.44; p,0.0001). CKD273 score was linearly
correlated with eGFR (R=20.64; p,0.001) (Figure 2), and with
urinary protein excretion (g/g), in a non-linear way (r=0.76;
p,0.001) (Figure S1).
Unsupervised clustering analysis taking into account the
individual values of the 273 peptides of the classifier separated
the patients into two small clusters (A and B, 2 patients each) and
two main clusters (C and D, 32 and 17 patients respectively)
(Figure 3). Cluster A included 2 diabetic patients in the 70 s with
heavy proteinuria and cluster B consisted of 2 diabetic patients
with important cardio-vascular co-morbidities (both died from
cardiac and vascular complications). There were significant
differences in laboratory parameters between cluster C and D.
Cluster C had a lower CKD273 scoring (p,0.0001) and higher
eGFR (p,0.01). Patients in cluster C also had lower blood urea
(p = 0.014), uric acid (p,0.01), urinary proteins (p = 0.002), PTH
(p= 0.01) and alkaline phosphatase levels (p,0.002) and higher
serum calcium level (p = 0.04), and red blood cell count (p = 0.013)
(Table S2).
To obtain further insight into the pathophysiological changes
associated with CKD, we investigated the correlation of the single
peptides that comprise the CKD273 pattern, with the estimated
glomerular filtration rate (eGFR). Several peptides revealed highly
significant correlations with the eGFR (Table S3).
Among the peptides that showed an inverse correlation with
eGFR, – increasing urinary relative concentrations with decreas-
ing renal function – most were derived from abundant plasma
proteins: b2-microglobulin, albumin, transthyretin, a-2HS glyco-
protein, APO A1 and a1-antitrypsin. In contrast, the peptides with
a positive correlation with eGFR – decreasing relative urinary
concentrations with progressive impairing in renal function – were
predominantly derived from constitutive renal proteins and
extracellular matrix : collagen type I (29 peptides) and type III
(8 peptides), Uromodulin, a protein locally synthesized in the renal
tubule (5 peptides), osteopontin and CD99.
A heatmap of the mean signal intensity of those peptides of the
CKD273 classifier which were present in .50% of the samples
and showed monotone variations, averaged in the four different
groups (stage I-II, III, IV and V) revealed a clearly distinct pattern
for the four groups (Figure 4-a). The median signal intensity for 2
of these peptides is plotted to illustrate the magnitude of the
differences observed between the groups according to their
estimated renal function (Figure 4-b and 4-c).
After 3.6 years of follow-up, the outcome was known for 49
patients (92.5%). All the patients having lost their renal function or
having died during follow-up had a very high CKD273 score
(Figure 5). There was a clear CDK273 cut-off value below which
patients did not progress to death or renal death during the follow-
up period. Conversely, urinary protein excretion showed good
specificity in identifying patients with high likelihood of end-stage
renal disease or death.
CKD273 score was correlated in a non-linear way with urinary
protein excretion expressed as g of protein/g of creatinine
(r=0.76; p,0.001) (shown in Figure S1). Despite the existing
relationship between CKD273 and urinary protein excretion
(Figure S1), their association with outcome was substantially
different (Figure 5). While a low score in the CKD273 classifier
identified those patients that would certainly not evolve to renal
loss or death, high urinary protein excretion would identify those
that would certainly evolve to renal loss and death during the
follow-up period (Figure 5).
Urinary Proteomics in Assessing CKD
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Discussion
CKD273, a urinary proteomics based classifier which was
developed to detect CKD irrespective of the underlying aetiology
[20], was able in the present study to blindly discriminate CKD
patients according to disease severity. Confirming the validity of
the data, unsupervised clustering analysis identified two main
groups that had different levels of renal function as demonstrated
by significant differences in blood urea level, eGFR, haemoglobin
and mineral bone markers status. The CKD273 classifier was
associated with the renal function level cross-sectionally at the
beginning of the follow-up study. More importantly, CKD273
Figure 1. The full urinary proteome/peptidome analysed by CE-MS of selected patients. Patient number 58 (A) and the diabetic patient 27
(B) are shown in the upper panels. These patients had eGFR of 64.3 and 15.7 ml/mn/1.73 m2, respectively. The molecular mass (0.8–20 kDa, on a
logarithmic scale) is plotted against normalized migration time (18–45 min). Signal intensity is encoded by peak height and color. The two lower
panels show only the peptides that are addressed in the CKD273 model. Differences already visible in the entire proteome become evident when
examining the specific biomarkers of the CKD273 classifier.
doi:10.1371/journal.pone.0062837.g001
Figure 2. CKD273 scoring and eGFR values in the patients included in the study. The patients treated by dialysis are not included in the
figure as their eGFR could not be calculated by the serum creatinine level. Linear Regression equation, y =20.019x +1.12; R2 = 0.40; p,0.001.
doi:10.1371/journal.pone.0062837.g002
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score was significantly higher in the patients who evolved towards
end-stage renal disease or died during the following years.
The information provided by the CKD273 classifier may be
exploited in two different ways. The first one is the intended value
of the classifier obtained as a composite single value in assessing
CKD, as supported by our present results. The second is to
analyze the different constitutive peptides separately following
their respective readouts. Individual analysis of the constitutive
peptides of the CKD273 classifier showed clear differences in
urinary levels of specific compounds that correlate with the degree
of renal function impairment as measured by eGFR. Since all 273
peptides constitutive of the CKD273 classifier are known, the
detection and quantification of these various compounds may offer
novel insights as markers of disease or perhaps even as compounds
involved in the disease process, although the latter has not yet been
proven.
The majority of peptides positively correlated with eGFR was
derived from collagen type I and type III, and from the locally
synthesized Uromodulin. The decrease in the abundance of these
peptides in urine may be related to a decrease in extracellular
matrix degradation, turnover, and organ repair, as well as to
fibrosis, which has been identified as a characteristic feature of the
late stages of renal diseases [26]. The data presented here argue for
a significant involvement in earlier stages of disease as well. These
findings are consistent with a previous report in diabetic patients
[17], showing that a hallmark of diabetic nephropathy is a
reduction in urinary collagen fragments. They are also in keeping
with Prajczer et al [27], who observed very low levels of urinary
Uromodulin as eGFR decreases. Osteopontin, a glycoprotein
highly expressed in renal failure [28], may also be related to
fibrosis, as it facilitates calcium oxalate monohydrate development
of interstitial fibrosis in hyperoxaluric states [29,30]. Based on our
results, these peptides and proteins likely display different facets of
the molecular pathophysiology of this heterogeneous disease.
Beyond the interest in identifying peptide products of different
pathways, clinical proteomics is primarily orientated at comple-
menting and improving the classical biomarkers, such as serum
creatinine level or albumin/creatinine urinary ratio. The CKD273
classifier previously proved to dissociate cases from controls in a
population including 230 patients with biopsy proven kidney
disease and 379 healthy subjects [20]. In the present work, we
show its correlation with CKD stage irrespective of the causal
kidney disease.
The longitudinal analyses of the clinical and biochemical data
support that CKD273 may inform about the likelihood of eGFR
decline and predicting CKD progression to end stage kidney
disease. The progress in proteomics and the use of multiple
biomarker classifiers open the possibility of establishing new tools
Figure 3. Cluster analysis. Clustering of the 53 patients was performed according to their CKD273 pattern using an average linkage clustering and
standard Euclidean distances to assign the patients to clusters.
doi:10.1371/journal.pone.0062837.g003
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adapted to different clinical needs. Some of them have been built
up to differentiate aetiology, others to assess CKD and CKD
progression. It is expected that with a more common use of
proteomics and with the sequence identification of the complete
urinary proteome, additional classifiers will be developed for
specific clinical applications, e.g. assessing specific CKD aetiology
like DN, and predicting both, disease progression and response to
therapy, based on prespecified molecular features.
Our present data show that proteomics may provide supple-
mentary information on aspects of CKD mainly unrelated to
serum creatinine level and derived estimates of glomerular
filtration rate, which inform about the likelihood of disease
progression. Indeed, National Kidney Foundation–CKD staging
has also allowed testing of the contribution of these technologies in
handling CKD patients. Although not routinely available,
proteomics is becoming more and more accessible, with increasing
Figure 4. Correlation of urinary peptides with kidney function. a) Heatmap of the signal of the 88 peptides of the CKD273 model showing
monotone variations. Each line represents a single peptide, and the four columns correspond to the four groups of patients separated according to
their eGFR value (90–61, 60–31, 30–16 and 15–0 mL/min/1.73 m2). The mean signal per peptide and per group is represented following the color key
included in the figure. b) and c): the median scoring and interquartile range for 2 of the 88 peptides is presented in logarithmic scale. The upper
panel shows the distribution of LLSPYSYSTTAVVTNPKE, a peptide derived from Transthyretin (AA 130–147). The lower panel depicts the distribution
of SGSVIDQSRVL, a peptide derived from Uromodulin (AA 589–599). The abundance of these peptides changes significantly with decreasing MDRD-
estimated GFR.
doi:10.1371/journal.pone.0062837.g004
Figure 5. Urinary protein excretion and CKD273 scoring at baseline and renal outcome. Patients were divided into 2 groups according to
their evolution during the follow-up period: Those that stayed alive and did not need dialysis and those that either died or needed dialysis. It can be
observed that urinary protein excretion was distributed in a wide range in the group of patients that needed dialysis or died (from normal to
nephrotic range), showing that although a high urinary protein excretion invariably resulted in renal failure progression, a low urinary protein
excretion did not preclude death or dialysis. At the right hand side can be observed that the CKD273 scoring of the patients that either died or
needed dialysis was clearly in a narrower range. None of the patients with low scores of CKD273 (,0,55) progressed to renal failure or died; a low
CKD273 score precluded death or need of dialysis in this population followed up for 3.6 years.
doi:10.1371/journal.pone.0062837.g005
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automation easing application and reducing costs. Proteomics has
enabled identification of new biomarkers of CKD with promising
clinical value [20]. The present study provides the first set of data
validating the CKD273 classifier in an independent cohort,
making it ready to be investigated for its prognostic value in large
populations on a long-term longitudinal basis.
Supporting Information
Figure S1 Correlation studies of Urinary protein excretion and
CKD273 classifier scoring. It can be observed that urinary protein
excretion and CKD273 scoring followed an exponential function
and were significantly correlated (Spearman z=0.76; p,0.0001).
(TIF)
Table S1 Clinical data and CKD273 classifier scoring of the
individual subjects in the study.
(XLS)
Table S2 Variables with significant differences when comparing
the 2 main clusters identified with the values of the CKD273
peptides (clusters C and D).
(XLS)
Table S3 Urinary peptides of the CKD273 model, which
significantly correlated with eGFR.
(XLS)
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